3/24
08:29 am
ucbjy
London School of Economics and Political Science Partners with Globality to Pioneer Use of AI-Driven Sourcing in Higher Education Sector [Yahoo! Finance]
Low
Report
London School of Economics and Political Science Partners with Globality to Pioneer Use of AI-Driven Sourcing in Higher Education Sector [Yahoo! Finance]
3/19
07:00 am
ucbjy
New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference
Low
Report
New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference
3/12
01:54 pm
ucbjy
Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome
Low
Report
Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome
3/7
08:26 am
ucbjy
BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis [Yahoo! Finance]
Low
Report
BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis [Yahoo! Finance]
3/7
08:26 am
ucbjy
BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden [Yahoo! Finance]
Low
Report
BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden [Yahoo! Finance]
3/7
08:00 am
ucbjy
BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden
Low
Report
BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden
3/7
08:00 am
ucbjy
BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis
Low
Report
BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis
2/27
07:00 am
ucbjy
On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth
Medium
Report
On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth
2/24
01:35 pm
ucbjy
Thymidine Kinase 2 Deficiency Market Insight, Epidemiology and Market Forecast to 2034 [Yahoo! Finance]
Low
Report
Thymidine Kinase 2 Deficiency Market Insight, Epidemiology and Market Forecast to 2034 [Yahoo! Finance]
1/16
07:28 am
ucbjy
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx) [Yahoo! Finance]
Low
Report
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx) [Yahoo! Finance]
1/16
07:00 am
ucbjy
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)
Low
Report
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)